Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179758 | 1.00 | RIPK1 (0.66) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL29595423 | 1.00 | RIPK1 (0.66) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2481688 | 1.00 | RIPK1 (0.66) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9378435 | 0.82 | RIPK1 (0.62) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9378268 | 0.82 | RIPK1 (0.62) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9378120 | 0.81 | RIPK1 (0.88) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9379168 | 0.81 | RIPK1 (0.63) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9383151 | 0.80 | RIPK1 (0.59) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12204414 | 0.80 | RIPK1 (0.62) | RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9370134 | 0.80 | RIPK1 (1.00) | RIPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908850-A1 | Target for therapy of cognitive impairment | The Johns Hopkins University (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20060014801-A1 | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-19 | — | — | US | claimed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| JP-11292764-A | — | — | None | — | — | JP | disclosed |
| WO-2022216953-A1 | COMPOUNDS FOR USE IN INCREASING FOXG1 EXPRESSION | BELIEVE IN A CURE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-1908850-B1 | Target for therapy of cognitive impairment | UNIV JOHNS HOPKINS (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2180888-A1 | NOVEL COMBINATIONS OF NERAMEXANE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Merz Pharma GmbH & Co. KGaA (DE) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009015844-A1 | NOVEL COMBINATIONS OF NERAMEXANE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-02-05 | — | — | WO | disclosed |
| EP-2018854-A1 | Novel combinations of neramexane for the treatment of neurodegenerative disorders | Merz Pharma GmbH & Co. KGaA (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | disclosed |
| WO-2004048551-A2 | TARGET FOR THERAPY OF COGNITIVE IMPAIRMENT | THE JOHNS HOPKINS UNIVERSITY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030050224-A1 | Blocking glutamate function at an ionotropic glutamate receptor. e.g., N-methyl-D-aspartate receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptor and the kainate receptor; brain disorders; spinal chord | NEDERGAARD MAIKEN (US) | 2003-03-13 | — | — | US | disclosed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | disclosed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | disclosed |
| JP-H11292764-A | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR DISEASE ASSOCIATED WITH GLUTAMIC ACID COMPOUND | MITSUI CHEM INC | 1999-10-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014801-A1 | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs | NNMT, NNT, SIRT5 | RIPK1 914/4885ALDH1A1 2071/4885CHRNB2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.